滚动资讯
FierceBiotechFDA hits Newron’s phase 3 schizophrenia trial with clinical hold in US after patient deathEndpoints NewsAbbVie faces questions about Skyrizi competition from J&JEndpoints NewsFDA, AstraZeneca prep for oncology adcommAgilentPCR Plate Sealer Market Leading Players Analysis - Agilent - openPR.comThermo FisherLeading biotech company launches its first US drug processing hub in Mass. - MassLive10x Genomics NewsWhy 10x Genomics Stock Is Sinking Today - TipRanksLonza NewsLonza Capsugel donates $50,000 to Project Hope Foundation - Index-JournalFierceBiotech阿斯利康在哮喘二期试验失败后放弃FLAP抑制剂FierceBiotech成本上升致GE HealthCare下调展望，重组业务部门及领导层FierceBiotech梯瓦制药以7亿美元收购Emalex，获得即将获批的图雷特综合征药物FierceBiotech阿斯利康重启英国3亿英镑投资，默克却按兵不动Cell小鼠初级嗅觉系统中社会气味的空间组织及检测
Endpoints News 2026年4月29日

AbbVie faces questions about Skyrizi competition from J&J

AbbVie faces questions about Skyrizi competition from J&J

原文
暂时没有全文，请查看原始来源。